Durlobactam is a new member of the diazabicyclooctane class of β-lactamase inhibitors with
broad spectrum activity against Ambler class A, C, and D serine β-lactamases. Sulbactam is …

Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination
in late-stage development for the treatment of Acinetobacter infections, including those …

Multidrug-resistant (MDR) Acinetobacter spp. poses a significant therapeutic challenge in
part due to the presence of chromosomally encoded β-lactamases, including class C …

Sulbactam-durlobactam is a β-lactam/β-lactamase inhibitor combination currently in
development for the treatment of infections caused by Acinetobacter, including multidrug …

Background Durlobactam is a broad-spectrum inhibitor of class A, C and D β-lactamases.
Sulbactam is a generic β-lactam most commonly used as a β-lactamase inhibitor in …

Multi-drug resistant (MDR) Acinetobacter baumannii is emerging as a pathogen of
increasing prevalence and concern. Infections associated with this Gram-negative pathogen …

Multidrug-resistant (MDR) bacterial infections are a serious threat to public health. Among
the most alarming resistance trends is the rapid rise in the number and diversity of β …

Avibactam is a diazabicyclooctane β-lactamase inhibitor possessing outstanding but
incomplete efficacy against multidrug-resistant Gram-negative pathogens in combination …

Objectives The production of a growing diversity of β-lactamases by Gram-negative bacteria
challenges antimicrobial chemotherapy. OP0595, discovered separately by each of Meiji …

ETX2514 is a non-β-lactam serine β-lactamase inhibitor in clinical development that has
greater potency and broader spectrum of β-lactamase inhibition than the related …